No Data
Shangrong Healthcare: Report for the third quarter of 2024
Shenzhen Glory Medical: Half-year report for the year 2024.
Shenzhen Glory Medical: Summary of Half-Year Report in 2024.
Shenzhen Glory Medical (002551.SZ): The net income in the first half of the year was 14.0266 million yuan, an increase of 21.41% year-on-year.
Gelonghui August 26th 丨 Shenzhen Glory Medical (002551.SZ) released the 2024 interim report, with reported revenue of 0.631 billion yuan, a year-on-year growth of 5.25%; net income attributable to shareholders of the listed company was 14.0266 million yuan; net income excluding non-recurring gains and losses attributable to shareholders of the listed company was 2.3089 million yuan, a year-on-year decrease of 65.32%; basic earnings per share 0.02 yuan.
Shenzhen Glory Medical (002551.SZ): Repurchase completed, a total of 2,999.47 million yuan was spent to repurchase 1,030,300 shares.
Shenzhen Glory Medical (002551.SZ) announced on June 7 that the deadline for the company's share buyback has expired as of the disclosure date of the announcement. As of the disclosure date of this announcement, the company has cumulatively repurchased 1,030,300 shares of the company's stock through the special securities account for repurchases in a centralized competitive bidding manner, accounting for 0.12% of the company's total share capital. The highest fill price was 3.10 yuan/share and the lowest fill price was 2.57 yuan/share, with a total amount paid of 2.99947 million yuan (excluding transaction fees).
Shang Rong Healthcare: No downward revisions to the “Shang Rong Bonds” conversion price
Shenzhen Shangrong Medical Co., Ltd. issued an announcement. As of May 24, 2024, the company's stock had triggered a downward revision of the “Shangrong Bonds” conversion price, but the board of directors decided not to revise the share conversion price downward this time, and will not propose a correction plan within the next six months.
No Data
No Data